Alisertib Sodium (MLN 8237 Sodium)is a selective Aurora A inhibitor that causes G2/M phase arrest and chromosomal misalignment, leading to tumour cell apoptosis, and can also inhibit STAT3 Tyr705 phosphorylation, resulting in downregulation of c-Myc expression.

Aurora B:396.5 nM, Aurora A:12.5 nM

Methods:
The anti-proliferative activity of Alisertib Sodium (MLN 8237 Sodium) was evaluated in various tumor cell lines. Cells were treated with the compound in vitro, and cell proliferation was measured to determine IC₅₀ values.
Results:
Alisertib Sodium exhibited significant anti-proliferative effects across different tumor cell lines, with IC₅₀ values ranging from 15 to 469 nM, indicating cell line-dependent sensitivity differences [4].

Methods:
To investigate the inhibitory effect of Alisertib Sodium (MLN 8237 Sodium) on colorectal tumor growth, a HCT-116 colon cancer xenograft model was established in nude mice. Mice were administered Alisertib orally at doses of 3, 10, or 30 mg/kg once daily for 3 consecutive weeks.
Results:
Alisertib Sodium significantly inhibited tumor growth in a dose-dependent manner. The tumor growth inhibition (TGI) rates for the 3, 10, and 30 mg/kg groups were 43.3%, 84.2%, and 94.7%, respectively [4].